Skip Navigation LinksHome > July 2010 - Volume 110 - Issue 7 > Labeling Changes For Simvastatin
AJN, American Journal of Nursing:
doi: 10.1097/01.NAJ.0000383929.92225.23
Drug Watch

Labeling Changes For Simvastatin

Aschenbrenner, Diane S. MS, APRN-BC

Collapse Box


* The lipid-lowering drug simvastatin can cause severe myopathy and rhabdomyolysis, especially at the highest approved dosage (80 mg per day).

* Rhabdomyolysis can lead to acute tubular necrosis or acute renal failure, which can be fatal.

* The risk of rhabdomyolysis is further increased when simvastatin is taken in combination with niacin by patients of Chinese descent.

© 2010 Lippincott Williams & Wilkins, Inc.


Article Tools


Article Level Metrics